Editas Medicine Inc - Company Profile

All the sales intelligence you need on Editas Medicine Inc in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Editas Medicine Inc fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Editas Medicine Inc.

Editas Medicine Inc: Segment Analysis

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Business Description

Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a gene editing company focused on developing genomic medicines. The company utilizes CRISPR gene editing technology to create medicines aimed at treating serious diseases. It has a diversified pre-clinical pipeline that encompasses investigational candidates targeted at the treatment, cancer, and hematologic diseases. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. Once the complex binds to the DNA sequence it is designed to recognize, the complex makes a specific cut in the DNA. In CRISPR technology, multiple guide RNAs can be provided along with the same endonuclease, enabling the simultaneous and efficient targeting of multiple sites.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

Editas's R&D arm focuses on translating the power and potential of gene editing into a broad class of differentiated and transformational medicines. The company is concentrating its research and development efforts on diseases with few or no available treatments, utilizing two distinct CRISPR nucleases: Cas9 and Cas12a (Cpf1). These nucleases enable the development of targeted and durable gene-edited medicines. Editas Medicine is actively pursuing in vivo gene editing medicines targeting hematopoietic stem cells, liver, and other tissue types. The company is developing experimental treatments for cardiovascular diseases, such as EDIT-401 for hyperlipidemia and atherosclerotic cardiovascular disease, and addressing blood diseases like sickle cell disease and beta thalassemia. The R&D unit of Editas is responsible for researching and developing in vivo gene editing medicines. The unit focuses on leveraging CRISPR nucleases to access a broad range of genetic mutations and develop targeted gene-edited medicines. The unit is also tasked with advancing the company's pipeline by focusing on functional upregulation and targeted delivery to specific tissues. In FY2025, the company spent US$89.9 million on its R&D activities, which declined 54.9% YoY and had 66 employees working on R&D Activities. As of December 2025, the company owned 85 US patents, 57 pending US non-provisional patent applications, 37 European patents and related validations, 57 pending European patent applications and 32 pending US provisional patent applications.

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Who We Are

Industries We Cover

Who We Serve

Corporates

Financial Institutions

Professional Services

Other

What We Offer

Intelligence Centers

Consultancy

Marketplace

Editas Medicine Inc - Company Profile

Editas Medicine Inc: Segment Analysis

Get in touch about GlobalData Company reports

Business Description

R&D Overview